NCT05143996View on ClinicalTrials.gov

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 18, 2021

Primary Completion Date

August 31, 2025

Study Completion Date

November 30, 2025

Conditions
Relapsed/Refractory Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)
Interventions
DRUG

CLN-049

\[FLT3\] x \[CD3\] bispecific T cell engager

Trial Locations (7)

10016

RECRUITING

New York University, New York

30322

RECRUITING

Emory University Hospital, Atlanta

33612

RECRUITING

Moffitt Cancer Center, Tampa

45229

RECRUITING

Cincinnati Children's Hospital Medical Center, Cincinnati

77030

RECRUITING

MD Anderson, Houston

90095

RECRUITING

UCLA, Los Angeles

02114

RECRUITING

Massachusetts General Hospital, Boston

Sponsors
All Listed Sponsors
lead

Cullinan Therapeutics Inc.

INDUSTRY

NCT05143996 - CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | Biotech Hunter | Biotech Hunter